<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02141945</url>
  </required_header>
  <id_info>
    <org_study_id>MB-01</org_study_id>
    <nct_id>NCT02141945</nct_id>
  </id_info>
  <brief_title>Microbiome Test for the Detection of Colorectal Polyps and Cancer</brief_title>
  <official_title>Metabiomics Neoplasia Clinical Research Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Metabiomics Corp</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Metabiomics Corp</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose if this study is to measure the sensitivity, specificity and accuracy of the&#xD;
      Metabiomics Colon Polyp and Colorectal Cancer Assay for the non-invasive detection of colon&#xD;
      polyps or colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to conduct clinical research to investigate the association of&#xD;
      the gut microbiome with colonic neoplasia. In this study patients will supply samples of&#xD;
      their gut microbiome prior to scheduled colonoscopy; the relative abundance of microbes from&#xD;
      those samples will be used to predict the presence or absence of colon polyps or colorectal&#xD;
      cancer. Microbiome based predictions from blinded samples will be compared with colonoscopy&#xD;
      and pathology results to quantify the sensitivity, specificity and accuracy (reported as %)&#xD;
      of the Metabiomics Colon Polyp and Colorectal Cancer Assay for colon polyps. The limited&#xD;
      sample size is anticipated to be insufficient to quantify sensitivity to colorectal cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2014</start_date>
  <completion_date type="Actual">March 1, 2017</completion_date>
  <primary_completion_date type="Actual">March 1, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Performance of Metabiomics Colon Polyp and Colorectal Cancer Assay</measure>
    <time_frame>1 year</time_frame>
    <description>Microbiome based predictions from at least 100 blinded samples will be compared with colonoscopy and pathology results to quantify the sensitivity, specificity and accuracy (reported as %) of the Metabiomics Colon Polyp and Colorectal Cancer Assay for colon polyps. The limited sample size is anticipated to be insufficient to quantify sensitivity to colorectal cancer.</description>
  </primary_outcome>
  <enrollment type="Actual">260</enrollment>
  <condition>Colorectal Neoplasms</condition>
  <condition>Colorectal Cancer</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      gut microbiome samples from stool, rectal and colonic mucosa&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients at average risk of developing colorectal cancer, scheduled for colonoscopy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female,&#xD;
&#xD;
          -  Age: 45-80 years,&#xD;
&#xD;
          -  Patients undergoing polyp surveillance or screening colonoscopy who are ASA Class 1-3.&#xD;
             No ASA Class 4 or 5 will be included.Footnote&#xD;
&#xD;
          -  All ethnic and racial groups will be included,&#xD;
&#xD;
          -  Able to comprehend, sign, and date the written informed consent form (ICF),&#xD;
&#xD;
          -  Able to give informed consent in English.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of Inflammatory Bowel Disease&#xD;
&#xD;
          -  Inability to schedule the colonoscopy within 60 days of the initial stool sample&#xD;
&#xD;
          -  Colonic pathology that in the opinion of the endoscopist could interfere with the&#xD;
             accuracy of the colonoscopy. Examples include: colonic stricture, poor preparation,&#xD;
             obstructing tumor.&#xD;
&#xD;
          -  ASA class 4 or greater&#xD;
&#xD;
          -  Vulnerable subjects. Students, nursing home residents, institutionalized patients, and&#xD;
             those with psychological or physical incapacity.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Hardi, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Metropolitan Gastroenterology Group</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Louis Korman, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Metropolitan Gastroenterology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DC Endoscopy Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chevy Chase Endoscopy Center</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://metabiomics.com/</url>
    <description>Click here for more information about the sponsor of this study, Metabiomics.</description>
  </link>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>May 14, 2014</study_first_submitted>
  <study_first_submitted_qc>May 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2014</study_first_posted>
  <last_update_submitted>March 27, 2017</last_update_submitted>
  <last_update_submitted_qc>March 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Colon Cancer</keyword>
  <keyword>Colorectal Cancer</keyword>
  <keyword>Neoplasm</keyword>
  <keyword>Colorectal Neoplasm</keyword>
  <keyword>Intestinal Neoplasms</keyword>
  <keyword>Gastrointestinal Neoplasms</keyword>
  <keyword>Digestive System Neoplasms</keyword>
  <keyword>Neoplasms by Site</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Colonic Diseases</keyword>
  <keyword>Digestive System Diseases</keyword>
  <keyword>Gastrointestinal Diseases</keyword>
  <keyword>Intestinal Diseases</keyword>
  <keyword>Rectal Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

